WYNNVISION LLC — Department of Health and Human Services SBIR Phase I: NHLBI

Description

Olga ZolotarskayaPhDPI PD Project TitleAntimicrobial and Biocompatible Endotracheal Tubes Abstract Ventilator associated pneumoniaVAPoccurshoursor morefollowing endotracheal intubation and accounts for half of all cases of hospital acquired pneumoniaCDC reports and many clinical studies point to a critical need for preventing ventilator associated infections rather than fighting an often losing battle against acquired infectionResponding to this unmet needWynnVision LLCWVwill leverage strong preliminary results for antimicrobial but cytocompatibleABCnanoovercoats on as manufactured intubation products to develop a new technology for eliminating or greatly reducing VAP VAEThe WV approachprotected by a recent patent applicationwill involve multidisciplinary activities and third party testing to facilitate approaching FDA for approvalKey Wordsendotracheal tubesovercoatantimicrobialbiocompatibility Project NarrativeRelevanceProject titleAntimicrobial and Biocompatible Endotracheal Tubes Ventilator associated pneumoniaVAPoccurshoursor morefollowing endotracheal intubation and accounts for about half of all cases of hospital acquired pneumoniaPatients who receive intubation include those who have suffered traumaneonatesthe elderly and the infirmAll are susceptible to VAP and related infections that are difficult to diagnosetreatment is often too lateWynnVision LLCWVaims to develop a new approach to prevent or greatly reduce the incidence of VAP and ventilator related infectionsThe new WV approach does not use antibiotics or antimicrobials that lead tosuper bugsand avoids heavy metals like silverIn summaryWV is aiming to prevent VAP and related infections with comfort and safety for patientsResults thus far show exciting promise for bringing much needed innovation for endotracheal tubes